GeoVax Labs Inc (GOVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeoVax Labs Inc (GOVX) has a cash flow conversion efficiency ratio of -1.266x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.21 Million) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GeoVax Labs Inc net asset quality index to measure how much of total assets are equity-financed.
GeoVax Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is GeoVax Labs Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
GeoVax Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeoVax Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
0.350x |
|
Avinger Inc
NASDAQ:AVGR
|
-0.738x |
|
Biosergen AS
ST:BIOSGN
|
-0.954x |
|
Labrador Technologies Inc
V:LTX
|
0.099x |
|
INVO Fertility, Inc.
NASDAQ:IVF
|
-0.304x |
|
INCUVO S.A. ZY -50
F:68X
|
0.135x |
|
Engineer Gold Mines Ltd
V:EAU
|
0.009x |
|
Yida China Holdings Ltd
STU:YC2
|
N/A |
Annual Cash Flow Conversion Efficiency for GeoVax Labs Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of GeoVax Labs Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see market value of GeoVax Labs Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.05 Million | $-24.68 Million | -4.888x | -11.90% |
| 2023-12-31 | $5.76 Million | $-25.17 Million | -4.368x | -510.53% |
| 2022-12-31 | $26.60 Million | $-19.03 Million | -0.715x | +72.13% |
| 2021-12-31 | $4.36 Million | $-11.20 Million | -2.567x | -792.97% |
| 2020-12-31 | $9.57 Million | $-2.75 Million | -0.287x | -132.36% |
| 2019-12-31 | $-1.57 Million | $-1.40 Million | 0.888x | -41.17% |
| 2018-12-31 | $-1.02 Million | $-1.54 Million | 1.510x | -71.29% |
| 2017-12-31 | $-321.06K | $-1.69 Million | 5.259x | +164.96% |
| 2016-12-31 | $240.37K | $-1.95 Million | -8.096x | -260.52% |
| 2015-12-31 | $1.20 Million | $-2.71 Million | -2.246x | -14.40% |
| 2014-12-31 | $1.15 Million | $-2.25 Million | -1.963x | -192.77% |
| 2013-12-31 | $2.53 Million | $-1.69 Million | -0.671x | +68.39% |
| 2012-12-31 | $1.15 Million | $-2.44 Million | -2.121x | -391.54% |
| 2011-12-31 | $703.61K | $-303.62K | -0.432x | +60.52% |
| 2010-12-31 | $1.84 Million | $-2.01 Million | -1.093x | -187.18% |
| 2009-12-31 | $3.74 Million | $-1.43 Million | -0.381x | +56.44% |
| 2008-12-31 | $2.71 Million | $-2.37 Million | -0.874x | +29.15% |
| 2007-12-31 | $2.65 Million | $-3.27 Million | -1.233x | -104.63% |
| 2006-12-31 | $2.20 Million | $-1.33 Million | -0.603x | -341.49% |
| 2005-12-31 | $-5.72 Million | $-1.43 Million | 0.250x | -0.01% |
| 2004-12-31 | $-4.95 Million | $-1.23 Million | 0.250x | +430.50% |
| 2003-12-31 | $-3.82 Million | $288.31K | -0.076x | +96.33% |
| 2001-12-31 | $2.05 Million | $-4.21 Million | -2.056x | -241.90% |
| 2000-12-31 | $10.52 Million | $-6.33 Million | -0.601x | +92.55% |
| 1999-12-31 | $552.34K | $-4.46 Million | -8.070x | -335.13% |
| 1998-12-31 | $2.89 Million | $-5.35 Million | -1.855x | -330.19% |
| 1997-12-31 | $5.68 Million | $-2.45 Million | -0.431x | -14.43% |
| 1996-12-31 | $3.09 Million | $-1.17 Million | -0.377x | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more